Siric > Research > Institutes > Institute for Functional Genomics (IGF)

Director: Jean-Philippe PINlogo-IGF-RVB-72dpi-png


General presentation

The IGF, a CNRS-INSERM-University laboratory created in 2005, is dedicated to studying the Genomics of cellular and intercellular signaling, with teams working on signal transduction in neuroscience, physiology and cancer biology, in close proximity with state-of-the-art technologies in genomics, proteomics, in vivo imaging and medium throughput analysis of signaling events. The IGF environment also fosters translational research and shares the campus of both the University Hospital Arnaud de Villeneuve and the new Faculty of Medicine. Several hospital physicians are affiliated to the IGF and contribute to the research projects in close collaboration with the scientists. IGF welcomes about 250 people – researchers, professors, engineers, technicians, postdocs and students – working into the 23 research teams, five technological platforms and research support services.

Research objectives and scientific productionimg.slide.igf.1

The IGF is devoted to understanding fundamental questions about human health and diseases through multidisciplinary research and technological innovation. The main research areas developed in are: Neuroscience (F. Ango, E. Bourinet, G. Lebon, P. Lory, N. Marchi, P. Marin, M.L. Parmentier, J. Perroy, J.P. Pin/L. Prézeau, F. Rassendren, E. Valjent), with projects covering both the normal physiology and different brain diseases, including epilepsy, mental retardation, depression, schizophrenia, pain psychiatric and neurodegenerative diseases. Physiology (S. Barrère-Lemaire/M. Mangoni, S. Dalle/M. Ravier, S. Granier, F. Jeanneteau, C. Jopling, P. Mollard, B. Mouillac, E. Renard), with activities ranging from molecular analyses, including structural biology, to clinical trials in the fields of diabetes, heart and kidney diseases, endocrine diseases, stress and learning diseases. Cancer Biology (F. Bienvenu, P. Jay, L. Journot, J. Pannequin), with focus on tumour initiation, progression and resistance to treatments, the relationship between the cell cycle machinery and cancer, and the epigenetic regulation of gene expression.

Facilities and platforms

The IGF is strongly involved in technological innovation and six facilities are present in the institute with 4 of them qualified ISO 9001 (MGX, FPP, IPAM and Arpege):

  • The genomics facility MGX for applications of next generation sequencing.
  • The proteomics facility FPP: mass spectrometric analyses of small biological samples
  • The in vivo imaging facility IPAM, dedicated to the development of specific microscopic setups aimed at visualizing fluorescent cells or probes in anesthetized animals.
  • The Pharmacology-screening facility Arpege: development of innovative technologies to quantify signaling cascades based on medium throughput analysis of biological interactions.
  • The animal facility, dedicated to the generation, maintenance and functional exploration of mouse models of human diseases.
  • The vectorology facility PVM for the production of recombinant viral particles

 Collaborations and valorisation

Most of the IGF teams work in the context of a network of national and international collaborators. The IGF has strong interactions with biotech companies, included one (BioRéalités, 2007) that was created as a spin-off of an IGF team and a cooperative laboratory with Cisbio has been established in 2010. Since 2012, 9 patents were filled by IGF teams.